Severe cognitive impairment associated with intrathecal antibodies to the NR1 subunit of the N-methyl-D-aspartate receptor in a patient with multiple sclerosis

JAMA Neurology

Volumn 72, Issue 1, 2015, Pages 96-99

  Fleischmann, Robert ^a   Prüss, Harald ^a   Rosche, Berit ^a   Bahnemann, Markus ^a   Gelderblom, Harald ^a   Deuschle, Katrin ^a   Harms, Lutz ^a   Kopp, Ute ^a   Ruprecht, Klemens ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GLATIRAMER; IMMUNOGLOBULIN G ANTIBODY; MITOXANTRONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; NATALIZUMAB; OLIGOCLONAL BAND; ANTIBODY; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NR1 NMDA RECEPTOR;

ADULT; AGGRESSIVENESS; AMNESIA; ANTI N METHYL D ASPARTATE RECEPTOR ENCEPHALITIS; ANTIBODY TITER; ARTICLE; ATAXIC GAIT; BEHAVIOR DISORDER; BLURRED VISION; BRAIN DAMAGE; CASE REPORT; CAUSE OF DEATH; CEREBROSPINAL FLUID EXAMINATION; COGNITIVE DEFECT; DELUSION; DEMENTIA; DISORIENTATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSARTHRIA; FACIAL NERVE PARALYSIS; FEMALE; HUMAN; HUMAN TISSUE; HYPESTHESIA; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE COUNT; LIP BIOPSY; MENTAL DETERIORATION; MINI MENTAL STATE EXAMINATION; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PLASMAPHERESIS; RELAPSE; SCHIRMER TEST; SIALOADENITIS; SJOEGREN SYNDROME; SOMNOLENCE; SPASTIC PARAPLEGIA; TEAR FLOW; TREATMENT WITHDRAWAL; URINE RETENTION; UROSEPSIS; WALKING DIFFICULTY; BLOOD; CEREBROSPINAL FLUID; COGNITION DISORDERS; COMPLICATION; IMMUNOLOGY; INTRASPINAL DRUG ADMINISTRATION;

ADULT; ANTIBODIES; COGNITION DISORDERS; FEMALE; HUMANS; INJECTIONS, SPINAL; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84921051016     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.1817     Document Type: Article

References (10)

1. Staff NP, Lucchinetti CF, Keegan BM. Multiple sclerosis with predominant, severe cognitive impairment. Arch Neurol. 2009;66(9):1139-1143.
2. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302.
3. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091-1098.
4. Titulaer MJ, Kayser MS, Dalmau J. Authors' reply. Lancet Neurol. 2013;12(5):425-426.
5. Finke C, Kopp UA, Prüss H, Dalmau J, Wandinger KP, Ploner CJ. Cognitive deficits following anti-NMDA receptor encephalitis. J Neurol Neurosurg Psychiatry. 2012;83(2):195-198.
6. Titulaer MJ, Höftberger R, Iizuka T, et al. Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol. 2014;75(3):411-428.
7. Uzawa A, Mori M, Takahashi Y, Ogawa Y, Uchiyama T, Kuwabara S. Anti-N-methyl D-aspartate-type glutamate receptor antibody-positive limbic encephalitis in a patient with multiple sclerosis. Clin Neurol Neurosurg. 2012;114(4):402-404.
8. Sandberg-Wollheim M, Axéll T, Hansen BU, et al. Primary Sjögren's syndrome in patients with multiple sclerosis. Neurology. 1992;42(4):845-847.
9. Killestein J, Vennegoor A, Strijbis EM, et al. Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol. 2010;68(3):392-395.
10. Stüve O, Cravens PD, Frohman EM, et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology. 2009;72(5):396-401.